Compare Mesoblast Limited (MESO) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Sony Group Corp — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Sony Group Corp trades at $24.03 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 78.2× Mesoblast Limited's market cap, and Sony Group Corp pays a 0.66% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Sony Group Corp for 96 Days on average.
| MESO | SONY | |
|---|---|---|
Market Cap | $1.75B | $136.87B |
Volume | 239,027 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $20.96 | $30.26 |
52-Week Low | $13.19 | $19.32 |
Typical Hold Time | 14 Days | 96 Days |
Enterprise Value | $1.83B | $134.77B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Sony trades at $23.52, down 1.38% on the day, with mixed technical signals showing a neutral overall trend. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with solid gross margins of 31.82%, though net income margin turned negative at -1.75% for 2026. Analyst sentiment remains bullish with 11 buy ratings versus 5 holds.
Sony presents a compelling value case with reasonable valuation multiples (P/E 19.93, P/S 1.75) and strong cash flow generation. However, recent negative profitability metrics and the Q1 2026 earnings miss highlight execution risks. The company's diversified entertainment portfolio and AI positioning offer growth potential, but investors should monitor margin recovery and content performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
